Teva Pharmaceuticals International and mAbxience have entered into a worldwide licencing agreement to develop an anti programmed cell death protein 1 oncology biosimilar candidate.
It is the second collaboration between the two entities, building on the partnership that began in April 2024.
The new global licencing agreement aims to develop an additional oncology biosimilar, reinforcing the alliance between Teva and mAbxience.
By combining their expertise and resources, the companies are committed to fostering innovation and improving healthcare accessibility for patients globally.
The agreement grants Teva exclusive rights for several markets, including Europe and the US.
It is in line with mAbxience’s strategy for expansion across the globe and reflects Teva’s efforts to grow its portfolio of biosimilars through strategic partnerships.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Teva business development executive vice-president Angus Grant said: “This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology treatments.
“This collaboration with mAbxience reflects Teva’s ideal strategic partnership model to optimise development costs, apply our regulatory expertise and leverage our extensive commercial capabilities to bring new treatment options to people living with serious medical conditions.”
As per the agreement, mAbxience will lead the development and manufacturing of the biosimilar, utilising its advanced certified good manufacturing practice-compliant (cGMP) facilities in Argentina and Spain.
Teva will be responsible for obtaining regulatory approvals and managing the commercialisation in the specified markets, aiming to provide access to this vital oncology treatment to patients worldwide.
mAbxience CEO Jurgen Van Broeck said: “Building on our first agreement with Teva signed earlier this year, this second collaboration is a testament to the strength of our partnership and the shared vision of both companies.
“This agreement reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale.”
Teva Pharmaceuticals has settled with the city of Baltimore in the US for $80m in September 2024, regarding its involvement in the opioid crisis. This settlement comes after Baltimore chose to opt out of a broader national case the previous year.
